These findings contribute to the understanding of the mechanisms by which EGFR-driven signaling networks control YAP/TAZ activation in normal cells and cancer, and support the therapeutic potential of inhibiting YAP/TAZ function in patients with cancers harboring EGFR alterations to enhance the response to EGFR targeted therapies, and prevent emergence of drug resistance. This evidence concerns the gene WWTR1 and cancer.